14 October 2022 : Clinical Research
Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
Zin W. Myint12ABCDEFG*, Jill M. Kolesar23CDE, Joseph Robert McCorkle2CDE, Jianrong Wu4C, Carleton S. Ellis32CDE, Danielle E. Otto23CDE, Peng Wang12ACDEDOI: 10.12659/MSM.938091
Med Sci Monit 2022; 28:e938091
Table 2 Summary of abiraterone trough concentration levels, prostate-specific antigen levels, germline HSD3B1, and survival data of all patients.
| Patient | bPSAa | PSAb | Trough AAb | PSAb | AAb | PSAb | AAb | BMIc | HSD3B1d | DSe | SSf | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Month | 3 Months | 7 Months | Statusg | Risk allele copy | ||||||||
| 1 | 57.65 | 34.56 | 28.50 | 16.11 | -- | -- | -- | 22.5 | DP | Dead | ||
| 2 | 132.5 | 3.07 | 5.51 | 0.55 | 20.93 | 0.02 | Refused | 35.8 | Homo (A/A) | 0 | CR | Alive |
| 3 | 246.0 | 1.65 | 7.89 | 0.23 | 12.50 | 1.25 | 26.86 | 31.7 | Hetero (C/A) | 1 | SD | Alive |
| 4 | 1536.0 | 7.44 | 4.55 | 1.66 | 7.09 | 0.41 | 3.58 | 32 | Homo (A/A) | 0 | PR | Alive |
| 5 | 735.6 | 3.78 | 240.46 | 1.95 | 18.22 | 0.84 | 21.37 | 31.5 | Homo (A/A) | 0 | PR | Alive |
| 6 | 73.56 | 3.06 | 9.01 | 0.25 | 16.28 | 0.08 | 14.68 | 23.5 | Homo (A/A) | 0 | PR | Alive |
| 7 | 150.2 | 18 | 3.36 | 11.90 | 2.91 | 5.86 | 4.60 | 35 | Hetero (C/A) | 1 | PR | Alive |
| 8 | 62 | 0.38 | 4.36 | 0.24 | 7.48 | 0.20 | 10.09 | 38.7 | Hetero (C/A) | 1 | PR | Alive |
| 9 | 1160 | 165.40 | 12.25 | 49.20 | 6.52 | -- | -- | 20.8 | Homo (A/A) | 0 | DP | Dead |
| 11 | 121.7 | 6.92 | 21.63 | 0.42 | 25.48 | 0.04 | 22.94 | 28.3 | Hetero (C/A) | 1 | SD | Alive |
| 12 | 122 | 5.86 | 81.82 | 0.27 | 29.96 | 0.03 | 21.80 | 31.4 | Homo (A/A) | 0 | SD | Alive |
| 13 | 68 | 1.92 | 17.25 | 0.65 | 4.84 | -- | -- | 27.2 | Hetero (C/A) | 1 | DP | Dead |
| a bPSA, PSA at diagnosis; b ng/mL; c BMI, body mass index; d allele 1245, rs1047303 (A=/C=); e DD, disease status; F SS, survival status; g homo (alleles) and hetero (alleles); CR – complete response; S – stable disease; PR – partial response; DP – disease progression. Bolded values are from patients that required dose-reduction after they went off the study. | ||||||||||||